Try our beta test site
IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. Read more...

VA111913 Dysmenorrhoea Efficacy and Safety Proof of Concept

This study has been completed.
Information provided by (Responsible Party):
Vantia Ltd Identifier:
First received: August 17, 2009
Last updated: May 6, 2014
Last verified: May 2014
The purpose of the study is to investigate how effective VA111913 is at preventing menstrual pain in women with primary dysmenorrhoea.

Condition Intervention Phase
Primary Dysmenorrhea
Drug: VA111913 TS and placebo
Phase 2

Study Type: Interventional
Study Design: Allocation: Randomized
Intervention Model: Crossover Assignment
Masking: Double Blind (Participant, Investigator, Outcomes Assessor)
Primary Purpose: Treatment
Official Title: A Randomised, Double Blind, Placebo Controlled, Multicentre, Cross Over Proof of Concept Study to Investigate the Efficacy and Safety of Pre Emptive Administration of Repeated, Oral Doses of VA111913 TS for the Alleviation of Dysmenorrhoea

Resource links provided by NLM:

Further study details as provided by Vantia Ltd:

Primary Outcome Measures:
  • Pain assessed using standard scoring system [ Time Frame: 3 months ]

Secondary Outcome Measures:
  • Safety assessed by laboratory findings, vital signs, ECGs and AEs [ Time Frame: 3 months ]
  • Assessment of treatment effectiveness [ Time Frame: 3 months ]
  • Requirement for rescue medication [ Time Frame: 3 months ]
  • Assessment of menstrual bleeding [ Time Frame: 3 months ]
  • PK assessments [ Time Frame: 3 months ]

Enrollment: 146
Study Start Date: August 2009
Study Completion Date: November 2010
Primary Completion Date: September 2010 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Experimental: VA111913 100mg twice daily Drug: VA111913 TS and placebo
VA111913 TS twice daily for a maximum of 6 days during one menstrual cycle followed by placebo twice daily for up to a maximum of 6 days during a second menstrual cycle in a cross over design
Placebo Comparator: Starch pill Drug: VA111913 TS and placebo
VA111913 TS twice daily for a maximum of 6 days during one menstrual cycle followed by placebo twice daily for up to a maximum of 6 days during a second menstrual cycle in a cross over design

Detailed Description:

Dysmenorrhoea is suffered by between 50% and 90% of women of child bearing age. Up to 30% of these women are non-responsive to the currently prescribed therapies. As such it represents an area of unmet medical need. VA111913 inhibits vasopressin-induced contractions of human myometrial strips and human myometrial blood vessels in vitro. By this mechanism, it is anticipated that the pain of dysmenorrhoea, a condition in which myometrial tone and contractions are increased and blood flow to the uterus is decreased compared to normal, may be reduced.

Subjects will be dosed with VA111913 TS and placebo in a cross over design during two consecutive menstrual cycles. They will be dosed for up to a maximum of 6 days, beginning 2 days before the onset of menstruation. Subjects will then assess the menstrual pain, bleeding and amount of analgesia required to treat symptoms during each cycle


Ages Eligible for Study:   18 Years to 35 Years   (Adult)
Sexes Eligible for Study:   Female
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • Women between 18 and 35 years old
  • Not pregnant
  • History of primary dysmenorrhoea
  • Regular menstrual cycles
  • Signed informed consent

Exclusion Criteria:

  • Known secondary dysmenorrhoea
  • Concomitant use of regular prescription or non prescription medications or herbal remedies
  • Any clinically significant medical history or active disease
  • Participation in another clinical study in the last 3 months
  • Contraindication to chosen rescue medications or allergy to their constituents
  • Other protocol defined eligibility criteria may apply
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT00963053

United States, Arizona
Pivotal Research Centers
Peoria, Arizona, United States, 85381
United States, Texas
Premier Research Group
Austin, Texas, United States, 78705
United States, Utah
Jean Brown Research
Salt Lake City, Utah, United States, 84124
United Kingdom
Bio-Kinetic Europe Limited
Belfast, United Kingdom, BT2 7BA
Sponsors and Collaborators
Vantia Ltd
Principal Investigator: David Bell Bio-Kinetic Europe Limited
Principal Investigator: Stephen E Daniels Premier Research Group plc
Principal Investigator: Vernon Yamashiro Jean Brown Research
Principal Investigator: Louise Taber Pivotal Research Centers
  More Information

Responsible Party: Vantia Ltd Identifier: NCT00963053     History of Changes
Other Study ID Numbers: 913-002
Study First Received: August 17, 2009
Last Updated: May 6, 2014

Keywords provided by Vantia Ltd:

Additional relevant MeSH terms:
Menstruation Disturbances
Pathologic Processes
Pelvic Pain
Neurologic Manifestations
Signs and Symptoms processed this record on May 25, 2017